Comparative Analysis: ExxonMobil (XOM) vs Dentsply Sirona (XRAY)
Compare: Swing Trader for Beginners: Trading in Markets Trending Up (TA&FA) - 6.34% for XOM vs 6.46% for XRAY
Investing in the stock market often boils down to comparing potential options. In this article, we provide a comparative analysis of ExxonMobil (XOM) and Dentsply Sirona (XRAY), focusing on price growth and earnings dates.
Swing Trading Performances
Our first point of analysis is the performance of Swing Trader for Beginners: Trading in Markets Trending Up (TA&FA) strategy for both stocks. XOM delivered a return of 6.34%, while XRAY slightly outperformed with a return of 6.46%. This shows that both stocks exhibited robust results with this swing trading approach, with XRAY offering marginally superior returns.
Price Growth
Next, we turn our attention to recent price growth. In the past week, XOM's price has decreased by 1.23%, while XRAY experienced a positive price change of 2.39%. This suggests that XRAY demonstrated a stronger performance over this short-term period.
In the broader industry context, the average weekly price growth for all stocks in the Integrated Oil industry (in which XOM operates) was 0.31%, compared to a decline of 0.88% in the Medical Specialties industry (where XRAY resides). However, looking at the longer-term trends, the average monthly and quarterly growth rates reveal a different story. The Integrated Oil industry experienced monthly and quarterly growth rates of 2.22% and 2.14% respectively, while the Medical Specialties industry faced a monthly decline of 0.37% but a strong quarterly growth of 7.41%.
Thus, while XRAY had a more robust weekly performance, the Medical Specialties industry's overall performance is mixed, with a negative monthly growth rate but a high quarterly growth rate. This emphasizes the importance of understanding both individual stock performances and broader industry trends when making investment decisions.
Upcoming Earnings Dates
Lastly, investors should note the upcoming earnings release dates for both companies. XOM is expected to report earnings on July 28, 2023, while XRAY is expected to release earnings a week later, on August 4, 2023. These dates are significant as earnings reports can significantly impact a stock's price and investor sentiment.
Conclusion
When comparing XOM and XRAY, investors need to consider various factors, including trading performance, price growth, and upcoming earnings dates. Both stocks performed well with the swing trading strategy, and XRAY displayed superior short-term price growth. However, investors must also consider the mixed industry performance, especially for XRAY. It's vital to monitor these factors and others to make informed decisions.
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
XOM saw its Momentum Indicator move above the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 61 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 67%.
The Moving Average Convergence Divergence (MACD) for XOM just turned positive on October 06, 2026. Looking at past instances where XOM's MACD turned positive, the stock continued to rise in 32 of 51 cases over the following month. The odds of a continued upward trend are 63%.
Following a +0.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where XOM advanced for three days, in 231 of 373 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XOM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
The Tickeron Profit vs. Risk Rating rating for this company is 6 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 28, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating fairly steady price growth. XOM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 62 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: XOM's P/B Ratio (2.577) is slightly higher than the industry average of (1.887). P/E Ratio (20.916) is within average values for comparable stocks, (16.521). Projected Growth (PEG Ratio) (1.392) is also within normal values, averaging (1.088). Dividend Yield (0.025) settles around the average of (0.035) among similar stocks. P/S Ratio (1.911) is also within normal values, averaging (3.764).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a distributer of crude oil, natural gas and petroleum products
Industry IntegratedOil